The importance of triaging in determining the quality of output from high-throughput screening

Future Medicinal Chemistry

Volumn 7, Issue 14, 2015, Pages 1847-1852

  Jones, Philip ^a   Mcelroy, Stuart ^a   Morrison, Angus ^a   Pannifer, Andrew ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

academic drug discovery; high throughput screening; PAINS; triaging

Indexed keywords

LEAD; DRUG;

CHEMICAL ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG SCREENING; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; MEDICAL RESEARCH; MEDICINAL CHEMISTRY; MOLECULAR WEIGHT; NOTE; NUCLEAR MAGNETIC RESONANCE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ROBOTICS; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; CHEMISTRY; DRUG INDUSTRY; ECONOMICS; METABOLISM; QUALITY CONTROL; STANDARDS;

DRUG DISCOVERY; DRUG INDUSTRY; HIGH-THROUGHPUT SCREENING ASSAYS; PHARMACEUTICAL PREPARATIONS; QUALITY CONTROL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84945267531     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.121     Document Type: Note

References (20)

1. Mullard A. 2014 FDA drug approvals. Nat. Rev. Drug Discov. 14(2), 77-81 (2015
2. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D. Nat. Rev. Drug Discov. 11(3), 191-200 (2012
3. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9(3), 203-214 (2010
4. Macarron R, Banks MN, Bojanic D, et al. Impact of highthroughput screening in biomedical research. Nat. Rev. Drug Discov. 10(3), 188-195 (2011
5. Dahlin JL, Walters MA. The essential roles of chemistry in high-Throughput screening triage. Future Med. Chem. 6(11), 1265-1290 (2014
6. Kuhnert M, Koster H, Bartholomaus R, et al. Tracing binding modes in hit-To-lead optimization: chameleon-like poses of aspartic protease inhibitors. Angew. Chem. Int. Ed. Engl. 54(9), 2849-2853 (2015
7. Soares KM, Blackmon N, Shun TY, et al. Profiling the NIH small molecule repository for compounds that generate H2O2 by redox cycling in reducing environments. Assay Drug Dev. Technol. 8(2), 152-174 (2010
8. Hermann JC, Chen Y, Wartchow C, et al. Metal impurities cause false positives in high throughput screening campaigns. ACS Med. Chem. Lett. 4(2), 197-200 (2013
9. Baell J, Walters MA. Chemical con artists foil drug discovery. Nature. 513(7519), 481-483 (2014
10. Seidler J, McGovern SL, Doman TN, Shoichet BK. Identification and prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem. 46(21), 4477-4486 (2003
11. Devine SM, Mulcair MD, Debono CO, et al. Promiscuous 2-Aminothiazoles (PrATs): a frequent hitting scaffold. J. Med. Chem. 58(3), 1205-1214 (2015
12. Brem J, van Berkel SS, Aik W, et al. Rhodanine hydrolysis leads to potent thioenolate mediated metallo-β-lactamase inhibition. Nat. Chem. 6, 1084-1090 (2014
13. Shoichet BK. Interpreting steep dose-response curves in early inhibitor discovery. J. Med. Chem. 49(25), 7274-7277 (2006
14. Hann MM, Keseru G. Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nat. Rev. Drug Discov. 11(5), 355-365 (2012
15. Academic Drug Discovery Consortium. www.addconsortium.org
16. Frye S, Crosby M, Edwards T, Juliano R. US academic drug discovery. Nat. Rev. Drug Discov. 10(6), 409-410 (2011
17. Tralau-Stewart C, Low CMR, Marlin N. UK academic drug discovery. Nat. Rev. Drug Discov. 13(1), 15-16 (2014
18. Shanks E, Ketteler R, Ebner D. Academic drug discovery within the United Kingdom: a reassessment. Nat. Rev. Drug Discov. 14(7), 510-513 (2015
19. Kogej T, Blomberg N, Greasley P, et al. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case. Drug Discov. Today. 18(19-20), 1014-1024 (2013
20. Besnard J, Jones PS, Hopkins AL, Pannifer AD. The Joint European Compound Library: boosting precompetitive research. Drug Discov. Today. 20(2), 181-186 (2015).